thonzylamine has been researched along with Esophageal Neoplasms in 1 studies
thonzylamine: major descriptor (72-84); file-maintained to PYRIMIDINES
Esophageal Neoplasms: Tumors or cancer of the ESOPHAGUS.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kobayashi, K | 1 |
| Kanetaka, K | 1 |
| Yoneda, A | 1 |
| Kobayashi, S | 1 |
| Maruya, Y | 1 |
| Isagawa, Y | 1 |
| Yoshimoto, T | 1 |
| Migita, K | 1 |
| Kawaguchi, Y | 1 |
| Kuba, S | 1 |
| Morita, M | 1 |
| Okada, S | 1 |
| Kosaka, T | 1 |
| Yamaguchi, S | 1 |
| Inoue, Y | 1 |
| Adachi, T | 1 |
| Hidaka, M | 1 |
| Torashima, Y | 1 |
| Ito, S | 1 |
| Takatsuki, M | 1 |
| Eguchi, S | 1 |
1 other study available for thonzylamine and Esophageal Neoplasms
| Article | Year |
|---|---|
Downstaging and Histological Effects Might Be Reliable Predictors of the Efficacy of DOC+CDDP+5-FU (DCF) as Neoadjuvant Therapy for Stage III or Borderline Resectable Esophageal Cancer: a Single Institute Experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Docetaxel; D | 2021 |